BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, April 24, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
March 30, 2020
View Archived Issues
New mouse model of MLL-ENL-driven AML to understand the early stages of leukemogenesis
Read More
Discovery of amide-linked benzimidazole-benzoxaborole hybrids for the treatment of onchocerciasis
Read More
Caelum initiates phase II study of CAEL-101 in AL amyloidosis
Read More
Phase II results for pembrolizumab in patients with advanced rare cancers
Read More
miR15a-1 as a new a noninvasive biomarker for asthma
Read More
Sepsis study may yield new treatment strategies
Read More
Dead cells do tell tales
Read More
TET1 gene therapy patented by the Military Medical Institute Academy
Read More
How lung tumors seed to brain
Read More
Roche synthesizes new TLR7/TLR8/TLR9 antagonists
Read More
Medshine Discovery discovers drugs targeting protein cereblon
Read More
New geranylgeranyl transferase type 1 inhibitors identified at Bayer
Read More
Abbisko Therapeutics identifies new fibroblast growth factor receptor inhibitors
Read More
Investigators describe biomarkers of liver injury
Read More
Gimsilumab completes phase I study in development of gimsilumab for COVID-19-related ARDS
Read More
NGM studies NGM-395 in obese adults and patients with NAFLD
Read More
New Chinese phase I study evaluates Ad5-nCoV coronavirus vaccine
Read More
Lundbeck discontinues foliglurax program in Parkinson's following phase IIa results
Read More
FDA approves new intravenous formulation of Triferic
Read More
Lundbeck reports phase IIa results with Lu-AG06466 in Tourette's syndrome
Read More
FDA approves Imfinzi as first-line treatment for extensive-stage SCLC
Read More